Cardiff Retained Earnings from 2010 to 2025

CRDF Stock  USD 2.06  0.02  0.98%   
Cardiff Oncology's Retained Earnings are decreasing over the last several years with slightly volatile swings. Retained Earnings are estimated to finish at about -365 M this year. Retained Earnings is the cumulative amount of net income that Cardiff Oncology retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals
 
Retained Earnings  
First Reported
2006-03-31
Previous Quarter
-397.6 M
Current Value
-411.6 M
Quarterly Volatility
111.7 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Cardiff Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cardiff Oncology's main balance sheet or income statement drivers, such as Selling General Administrative of 7.9 M, Other Operating Expenses of 51.8 M or Research Development of 38.7 M, as well as many indicators such as Price To Sales Ratio of 204, Dividend Yield of 0.0074 or PTB Ratio of 2.37. Cardiff financial statements analysis is a perfect complement when working with Cardiff Oncology Valuation or Volatility modules.
  
Build AI portfolio with Cardiff Stock
Check out the analysis of Cardiff Oncology Correlation against competitors.
For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.

Latest Cardiff Oncology's Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Cardiff Oncology over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Cardiff Oncology's Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cardiff Oncology's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (384.18 M)10 Years Trend
Slightly volatile
   Retained Earnings   
       Timeline  

Cardiff Retained Earnings Regression Statistics

Arithmetic Mean(187,018,715)
Geometric Mean146,497,092
Coefficient Of Variation(62.98)
Mean Deviation97,879,338
Median(173,046,186)
Standard Deviation117,782,389
Sample Variance13872.7T
Range348.3M
R-Value(0.99)
Mean Square Error329.2T
R-Squared0.98
Slope(24,463,734)
Total Sum of Squares208090.4T

Cardiff Retained Earnings History

2025-365 M
2024-384.2 M
2023-339.5 M
2022-298.1 M
2021-259.8 M
2020-231.5 M
2019-208.9 M

Other Fundumenentals of Cardiff Oncology

Cardiff Oncology Retained Earnings component correlations

0.96-0.550.96-0.29-0.630.350.640.190.160.870.550.84-0.62-0.110.640.510.63-0.510.920.92-0.77
0.96-0.570.99-0.22-0.710.460.750.050.080.950.490.84-0.68-0.210.730.530.67-0.590.970.97-0.86
-0.55-0.57-0.590.220.33-0.29-0.27-0.13-0.27-0.53-0.29-0.380.330.02-0.35-0.270.170.25-0.5-0.50.41
0.960.99-0.59-0.29-0.710.510.750.180.150.950.530.82-0.67-0.130.710.520.67-0.540.940.94-0.83
-0.29-0.220.22-0.290.34-0.14-0.25-0.260.16-0.18-0.44-0.280.37-0.16-0.31-0.31-0.070.29-0.19-0.190.17
-0.63-0.710.33-0.710.34-0.71-0.85-0.030.14-0.79-0.71-0.90.910.02-0.94-0.87-0.450.85-0.72-0.720.71
0.350.46-0.290.51-0.14-0.710.760.3-0.010.620.40.51-0.5-0.060.550.480.35-0.380.450.45-0.43
0.640.75-0.270.75-0.25-0.850.760.0-0.180.830.420.78-0.69-0.210.790.640.64-0.640.770.77-0.69
0.190.05-0.130.18-0.26-0.030.30.00.630.040.33-0.010.030.62-0.11-0.040.110.35-0.09-0.10.06
0.160.08-0.270.150.160.14-0.01-0.180.63-0.020.23-0.110.080.56-0.12-0.19-0.070.27-0.11-0.110.09
0.870.95-0.530.95-0.18-0.790.620.830.04-0.020.410.85-0.66-0.250.750.550.67-0.580.940.94-0.88
0.550.49-0.290.53-0.44-0.710.40.420.330.230.410.69-0.850.320.710.790.15-0.710.450.46-0.37
0.840.84-0.380.82-0.28-0.90.510.78-0.01-0.110.850.69-0.85-0.120.880.820.53-0.820.860.86-0.76
-0.62-0.680.33-0.670.370.91-0.5-0.690.030.08-0.66-0.85-0.850.02-0.95-0.89-0.330.91-0.69-0.690.63
-0.11-0.210.02-0.13-0.160.02-0.06-0.210.620.56-0.250.32-0.120.02-0.130.15-0.220.18-0.34-0.340.24
0.640.73-0.350.71-0.31-0.940.550.79-0.11-0.120.750.710.88-0.95-0.130.850.41-0.90.730.74-0.68
0.510.53-0.270.52-0.31-0.870.480.64-0.04-0.190.550.790.82-0.890.150.850.21-0.870.570.57-0.44
0.630.670.170.67-0.07-0.450.350.640.11-0.070.670.150.53-0.33-0.220.410.21-0.240.670.67-0.63
-0.51-0.590.25-0.540.290.85-0.38-0.640.350.27-0.58-0.71-0.820.910.18-0.9-0.87-0.24-0.64-0.650.57
0.920.97-0.50.94-0.19-0.720.450.77-0.09-0.110.940.450.86-0.69-0.340.730.570.67-0.641.0-0.88
0.920.97-0.50.94-0.19-0.720.450.77-0.1-0.110.940.460.86-0.69-0.340.740.570.67-0.651.0-0.87
-0.77-0.860.41-0.830.170.71-0.43-0.690.060.09-0.88-0.37-0.760.630.24-0.68-0.44-0.630.57-0.88-0.87
Click cells to compare fundamentals

About Cardiff Oncology Financial Statements

Cardiff Oncology stakeholders use historical fundamental indicators, such as Cardiff Oncology's Retained Earnings, to determine how well the company is positioned to perform in the future. Although Cardiff Oncology investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cardiff Oncology's assets and liabilities are reflected in the revenues and expenses on Cardiff Oncology's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cardiff Oncology. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Retained Earnings-384.2 M-365 M
Retained Earnings Total Equity-268.3 M-281.7 M

Currently Active Assets on Macroaxis

When determining whether Cardiff Oncology is a strong investment it is important to analyze Cardiff Oncology's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cardiff Oncology's future performance. For an informed investment choice regarding Cardiff Stock, refer to the following important reports:
Check out the analysis of Cardiff Oncology Correlation against competitors.
For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.
You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiff Oncology. If investors know Cardiff will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiff Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.87)
Revenue Per Share
0.009
Quarterly Revenue Growth
(0.26)
Return On Assets
(0.48)
Return On Equity
(0.92)
The market value of Cardiff Oncology is measured differently than its book value, which is the value of Cardiff that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiff Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cardiff Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiff Oncology's market value can be influenced by many factors that don't directly affect Cardiff Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiff Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiff Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiff Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.